Long-Term Clinical Outcomes of Polymer-Free Sirolimus-Eluting Stent and Polymer-Coated Sirolimus-Eluting Stent in Patients with Type 2 Diabetes
Ou Yang,Yuhuan Teng,Ruoxi Zhang,Jie Qu
DOI: https://doi.org/10.2147/ijn.s482608
IF: 7.033
2024-11-13
International Journal of Nanomedicine
Abstract:Ou Yang, 1 Yuhuan Teng, 1 Ruoxi Zhang, 2 Jie Qu 1 1 Department of Cadre Ward, The First Hospital of Jilin University, Changchun, Jilin, 130021, People's Republic of China; 2 Department of Cardiology, Harbin Yinghua Hospital, Harbin, Heilongjiang, 150199, People's Republic of China Correspondence: Jie Qu; Ruoxi Zhang, Email ; Introduction: Polymer-free sirolimus-eluting stent (PF-SES) possess multiple properties improving targeted drug elution and in-stent reendothelialization without the presence of polymers. The long-term clinical performance comparison between PF-SES and the latest generation polymer-coated sirolimus-eluting stents (SES), particularly regarding intravascular imaging assessment and in the type 2 diabetes mellitus (DM) population, remains unexplored. Methods: We conducted a retrospective study involving 2646 diabetes patients meeting coronary artery disease (CAD) criteria underwent coronary stents in the real-world. All patients were divided into the PF-SES group and the SES group. Optical coherence tomography (OCT) was used to evaluate the imaging characteristics of in-stent reendothelialization. Patient information between the two groups was systematically compared in hospital and at 5-year follow-up. Results: In terms of basic characteristics, the proportion of current smoker and stable angina patients in the PF-SES group was significantly higher than that in the SES group. The PF-SES group exhibited significantly higher rate of left anterior descending (LAD) lesion and more stents per patients compared to the SES group. The value of minimum lumen area (MLA), neointimal area (NA) and neointimal thickness (NT) were higher in the PF-SES group. Additionally, the occurrence rates of heterogeneous, lipid layer, intimal tears, thrombi, and micro-vessels were notably lower in the PF-SES group compared to the SES group. A higher all-cause mortality was observed in the SES cohort. Discussion: PF-SES could effectively improve in-stent reendothelialization in patients with type 2 DM, with positive effects on survival rate and may, therefore, be considered as an alternative treatment option for improving clinical long-term outcomes. Keywords: Polymer-free, polymer-coated, Nano Plus stent, drug-eluting stents, type 2 diabetes mellitus, optical coherence tomography Since the advent of drug-eluting stents (DES), significant advancements have been achieved in the management of coronary artery disease. The replacement of bare-metal stents with DES in standard clinical practice has led to noticeable decreases in in-stent restenosis and target lesion revascularization. 1 However, it has been observed that DES carry a heightened risk of late stent thrombosis due to delayed reendothelialization. 2,3 The durable polymer has been shown to cause vessel wall inflammation and hinder arterial healing, potentially increasing the risk of late thrombosis. 4,5 Polymer-free technologies have since emerged, with polymer-free DES designed to prevent adverse events resulting from hypersensitivity reactions and chronic inflammation associated with polymers. 6,7 It is important to note that inflammation is considered a contributing factor in the development of type 2 diabetes mellitus (DM). A growing body of evidence indicates that inflammation plays a critical intermediary role in its pathogenesis. Substantial experimental data and extensive cross-sectional studies suggest that interleukin 6 (IL-6) and C-reactive protein (CRP), sensitive markers of sub-clinical systemic inflammation, are linked to hyperglycemia, insulin resistance, and overt type 2 DM. 8,9 Therefore, we hypothesize that in diabetic patients experiencing heightened inflammation, the use of polymer-coated stents may worsen the inflammatory response. This, in turn, could impede vascular reendothelialization after stent implantation, ultimately affecting clinical outcomes. This study aimed to evaluate the long-term clinical outcomes of polymer-free sirolimus-eluting stents (PF-SES) in comparison to polymer-coated sirolimus-eluting stents (SES) in patients with type 2 DM. This retrospective analysis included 2646 consecutive diabetes patients with coronary artery disease (CAD) who underwent coronary stents at The First Bethune Hospital of Jilin University. Patients were divided into two groups according to the type of coronary stents they received: PF-SES and SES (Figure 1). Patients diagnosed with type 2 DM were eligible for inclusion if they exhibited clinical symptoms of ischemia, indicating the presence of coronary artery stenosis necessitating the use of coronary stents. 10 The eligibility criteria for patient inclusion: (i) confirmed diagnosis of type -Abstract Truncated-
pharmacology & pharmacy,nanoscience & nanotechnology